PT914097E - Composicao e forma de dosagem compreendendo antagonista de opioide - Google Patents

Composicao e forma de dosagem compreendendo antagonista de opioide

Info

Publication number
PT914097E
PT914097E PT97908764T PT97908764T PT914097E PT 914097 E PT914097 E PT 914097E PT 97908764 T PT97908764 T PT 97908764T PT 97908764 T PT97908764 T PT 97908764T PT 914097 E PT914097 E PT 914097E
Authority
PT
Portugal
Prior art keywords
composition
dosage form
antagonist
opioide
comprehending
Prior art date
Application number
PT97908764T
Other languages
English (en)
Inventor
Jerry D Childers
Antony L Kuczynski
Glen E Barclay
Sonya Merrill
Susan Rogriguez
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of PT914097E publication Critical patent/PT914097E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
PT97908764T 1996-03-12 1997-02-28 Composicao e forma de dosagem compreendendo antagonista de opioide PT914097E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1329096P 1996-03-12 1996-03-12

Publications (1)

Publication Number Publication Date
PT914097E true PT914097E (pt) 2002-06-28

Family

ID=21759200

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97908764T PT914097E (pt) 1996-03-12 1997-02-28 Composicao e forma de dosagem compreendendo antagonista de opioide

Country Status (10)

Country Link
US (1) US5866164A (pt)
EP (1) EP0914097B1 (pt)
AT (1) ATE211906T1 (pt)
AU (1) AU2059297A (pt)
DE (1) DE69709646T2 (pt)
DK (1) DK0914097T3 (pt)
ES (1) ES2168610T3 (pt)
HK (1) HK1019705A1 (pt)
PT (1) PT914097E (pt)
WO (1) WO1997033566A2 (pt)

Families Citing this family (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103258A (en) * 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
WO1998035679A1 (de) * 1997-02-14 1998-08-20 Gödecke Aktiengesellschaft Stabilisierung von naloxonhydrochlorid
US6559158B1 (en) * 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
ES2415876T3 (es) 1997-12-22 2013-07-29 Euro-Celtique S.A. Forma de dosificación farmacéutica oral que comprende una combinación de un agonista de opiáceos y un antagonista de opiáceos
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
TR200001828T2 (tr) * 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid dozaj şekillerinin kötüye kullanımını önlemeye yönelik bir yöntem.
IT1302682B1 (it) 1998-10-16 2000-09-29 Formenti Farmaceutici Spa Composizioni farmaceutiche orali contenenti buprenorfina
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
US6541021B1 (en) 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US6835194B2 (en) 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
WO2000069416A1 (en) * 1999-05-13 2000-11-23 Unihart Corporation Pharmaceutical compositions comprising apocodeine and/or its derivatives
IL149352A0 (en) 1999-10-29 2002-11-10 Euro Celtique Sa Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
CN101703777B (zh) * 2000-02-08 2012-11-28 欧罗赛铁克股份有限公司 抗破坏口服阿片样激动剂
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US7074803B2 (en) * 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
KR20030036157A (ko) 2000-04-07 2003-05-09 탭 파마슈티칼 프로덕츠 인코포레이티드 아포모르핀 유도체 및 이의 사용 방법
US20030190290A1 (en) * 2000-06-22 2003-10-09 Calvin Ross Pharmaceutical compositions
JP2004512354A (ja) * 2000-10-30 2004-04-22 ユーロ−セルティーク，エス．エイ． ヒドロコドン放出制御製剤
EP1341536A4 (en) 2000-11-15 2007-08-01 Tap Pharmaceutical Prod Inc TREATMENT OF SEXUAL DYSFUNCTION CAUSED BY ANTIDEPRESSIVE MEDICATION BY APOMORPHINE
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
EP1389092B1 (en) * 2001-05-11 2006-11-15 Endo Pharmaceuticals Inc. Abuse-resistant opioid dosage form
EP1387673B1 (en) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
AU2002339378A1 (en) 2001-05-22 2002-12-03 Euro-Celtique Compartmentalized dosage form
DE60234183D1 (de) * 2001-06-05 2009-12-10 Univ Chicago Verwendung von methylnaltrexon zur behandlung von immunsuppression
PT1416842E (pt) * 2001-07-18 2009-03-31 Euro Celtique Sa Composições farmacêuticas de oxicodona e naloxona
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
KR20040029405A (ko) 2001-08-06 2004-04-06 유로-셀티크 소시에떼 아노뉨 방출성 및 격리된 길항제와 오피오이드 효능제의 제제
WO2003013433A2 (en) * 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
SI1436012T1 (en) 2001-10-18 2018-03-30 Nektar Therapeutics Polymer conjugates of opioid antagonists
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US20030229111A1 (en) * 2002-03-14 2003-12-11 Benjamin Oshlack Naltrexone hydrochloride compositions
EP3241548A1 (en) 2002-04-05 2017-11-08 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
AU2003245345A1 (en) * 2002-05-31 2003-12-19 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US7771707B2 (en) 2004-06-12 2010-08-10 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
WO2004014336A2 (de) * 2002-08-09 2004-02-19 Grünenthal GmbH Opiod-rezeptor-antagonisten in transdermalen systemen mit buprenorphin
WO2004026256A2 (en) * 2002-09-20 2004-04-01 Alpharma, Inc. Sustained-release opioid formulations and methods of use
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
DE10250084A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10250088A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10250087A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20050191244A1 (en) * 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
US20050186139A1 (en) * 2002-10-25 2005-08-25 Gruenenthal Gmbh Abuse-proofed dosage form
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
US8293799B2 (en) * 2003-12-29 2012-10-23 Osmotica Keresleedelmo és Szolgáltató KFT Osmotic device containing a venlafaxine salt and a salt having an ion in common
ES2360102T3 (es) 2003-03-26 2011-05-31 Egalet A/S Sistema para la liberación controlada de morfina.
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
CA2521420A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
RU2373936C2 (ru) * 2003-04-08 2009-11-27 Проджиникс Фармасьютикалз, Инк. Применение метилналтрексона для лечения синдрома раздраженного кишечника
DK1615646T4 (da) * 2003-04-08 2022-10-10 Progenics Pharm Inc Farmaceutiske formuleringer, der indeholder methylnaltrexon
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
MXPA05011557A (es) 2003-04-29 2006-03-09 Orexigen Therapeutics Inc Composiciones para afectar perdida de peso.
EP2316440A1 (en) * 2003-04-30 2011-05-04 Purdue Pharma L.P. Transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer and one fluid communication between the surface of the active agent and the adverse agent
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
PL1842533T3 (pl) * 2003-08-06 2013-08-30 Gruenenthal Gmbh Postać aplikacyjna zabezpieczona przed nadużyciem
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032051A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
PT1663229E (pt) * 2003-09-25 2010-07-13 Euro Celtique Sa CombinaãŽes farmac—uticas de hidrocodona e naltrexona
US20050089570A1 (en) * 2003-09-26 2005-04-28 Evangeline Cruz Oros push-stick for controlled delivery of active agents
US20050158382A1 (en) * 2003-09-26 2005-07-21 Evangeline Cruz Controlled release formulations of opioid and nonopioid analgesics
ATE544447T1 (de) * 2003-09-26 2012-02-15 Alza Corp Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
AU2004299138B2 (en) * 2003-12-16 2010-03-25 Nektar Therapeutics Chemically Modified Small Molecules
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
CA2572352A1 (en) * 2004-07-01 2006-01-12 Gruenenthal Gmbh Oral dosage form safeguarded against abuse containing (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
FI1765303T4 (fi) * 2004-07-01 2023-01-31 Väärinkäytöltä suojattu oraalinen tabletti
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
EP1845989A1 (en) * 2005-01-20 2007-10-24 Progenics Pharmaceuticals, Inc. Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
EP1810678A1 (de) 2006-01-19 2007-07-25 Holger Lars Hermann Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
HUE032156T2 (en) 2006-06-19 2017-09-28 Alpharma Pharmaceuticals Llc Pharmaceutical preparations
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
US20080233156A1 (en) * 2006-10-11 2008-09-25 Alpharma, Inc. Pharmaceutical compositions
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
CA2674915C (en) 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
US8088786B2 (en) 2006-11-09 2012-01-03 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
WO2008060964A2 (en) * 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
CA2865389A1 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
SI2565195T1 (sl) 2007-03-29 2015-09-30 Wyeth Llc Periferalni opioidni receptorji in antagonisti in njih uporaba
TWI466671B (zh) 2007-03-29 2015-01-01 Progenics Pharm Inc 末梢性類鴉片受體拮抗劑及其用途
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
SI2197429T1 (sl) 2007-09-03 2016-09-30 Nanotherapeutics, Inc. Sestavki iz delcev za vnos slabo topnih zdravil
AU2014250614B2 (en) * 2007-09-04 2016-11-10 Alpharma Pharmaceuticals, Llc A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
WO2009032270A2 (en) * 2007-09-04 2009-03-12 Alpharma, Inc. A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
WO2009088673A2 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
BRPI0821732A2 (pt) 2007-12-17 2015-06-16 Labopharm Inc Formulações de liberação controlada , forma de dosagem sólida, e, uso da formulação de liberação controlada
US20090196890A1 (en) * 2007-12-17 2009-08-06 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
CA2709950A1 (en) * 2007-12-17 2009-07-09 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
AU2008338439A1 (en) * 2007-12-17 2009-06-25 Alpharma Pharmaceuticals. Llc Pharmaceutical composition
AU2015200313B2 (en) * 2007-12-17 2016-12-01 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
AU2009245777B2 (en) * 2008-05-05 2013-06-06 Euro-Celtique S.A. Opioid composition for treating skin lesions
EP2273983B1 (en) 2008-05-09 2016-07-20 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
JP2011521973A (ja) * 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
CA2730211C (en) * 2008-07-07 2016-11-08 Euro-Celtique S.A. Use of opioid antagonists for treating urinary retention
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2010096045A1 (en) 2008-10-30 2010-08-26 Nectid, Inc. Novel and potent tapentadol dosage forms
EP2367541B1 (en) 2008-12-16 2014-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
MX347106B (es) 2009-03-10 2017-04-12 Euro-Celtique S A * Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
BRPI1010301A2 (pt) * 2009-04-09 2016-03-15 Alkermes Pharma Ireland Ltd composição.
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
JP5667183B2 (ja) 2009-07-22 2015-02-12 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 加熱溶融押出成型した制御放出性投与剤型
ES2560210T3 (es) 2009-07-22 2016-02-17 Grünenthal GmbH Forma de dosificación resistente a la manipulación para opiádes sensibles a la oxidación
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
ES2606227T3 (es) * 2010-02-03 2017-03-23 Grünenthal GmbH Preparación de una composición farmacéutica en polvo mediante una extrusora
IT1398930B1 (it) * 2010-03-24 2013-03-28 Molteni & C Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi.
WO2012007159A2 (en) 2010-07-14 2012-01-19 Grünenthal GmbH Novel gastro-retentive dosage forms
KR20130137627A (ko) 2010-09-02 2013-12-17 그뤼넨탈 게엠베하 음이온성 중합체를 포함하는 내변조성 투여형
RU2604676C2 (ru) 2010-09-02 2016-12-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
EP2446882B8 (de) 2010-10-28 2014-02-12 Acino Pharma AG Arzneimittel mit dem Wirkstoff Hydromorphon mit verbesserter Lagerstabilität
CN103328038A (zh) 2010-12-01 2013-09-25 史拜诺莫度雷森公司 向神经解剖结构直接递送药剂
KR101572336B1 (ko) 2010-12-22 2015-11-26 퍼듀 퍼머 엘피 케이싱된 탬퍼 저항성 제어 방출 투여 형태
CN103327969A (zh) 2010-12-23 2013-09-25 普渡制药公司 抗篡改固体口服剂型
WO2013017234A1 (en) 2011-07-29 2013-02-07 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
AR087359A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
PE20141198A1 (es) 2011-09-19 2014-10-05 Orexo Ab Nueva composicion farmaceutica resistente al abuso para el tratamiento de la dependencia de opioides
BR112014011504A2 (pt) * 2011-11-17 2017-05-09 Gruenenthal Gmbh forma de dosagem farmacêutica oral inviolável compreendendo ingrediente farmacologicamente ativo, antagonista opioide e/ou agente aversivo, óxido de polialquileno e polímero aniônico
US20150224097A1 (en) * 2011-11-22 2015-08-13 Watson Pharmaceuticals, Inc. Immediate Release Abuse Deterrent Tablet
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
ES2692944T3 (es) 2012-04-18 2018-12-05 Grünenthal GmbH Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
ES2924024T3 (es) 2012-06-06 2022-10-04 Nalpropion Pharmaceuticals Llc Composición para su uso en un método para el tratamiento del sobrepeso y la obesidad en pacientes con alto riesgo cardiovascular
WO2014006004A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
EA201500742A1 (ru) 2013-02-05 2015-12-30 Пердью Фарма Л.П. Защищенные от нецелевого использования фармацевтические композиции
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9517208B2 (en) 2013-03-15 2016-12-13 Purdue Pharma L.P. Abuse-deterrent dosage forms
EP3003283A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
CA2914365C (en) 2013-06-05 2022-03-15 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EA032465B1 (ru) 2013-07-12 2019-05-31 Грюненталь Гмбх Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления
EP3024461B1 (en) 2013-07-23 2020-05-13 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CN106572980A (zh) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 包含他喷他多的防篡改即释胶囊制剂
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
JP6371463B2 (ja) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 即時放出性乱用抑止性液体充填剤形
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
KR20170139158A (ko) 2015-04-24 2017-12-18 그뤼넨탈 게엠베하 즉시 방출되고 용매 추출 방지된 변조 방지된 투여 형태
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
US20170312226A1 (en) * 2016-04-28 2017-11-02 Ascent Pharmaceuticals, Inc. Pharmaceutical dosage forms
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4036228A (en) * 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111201A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
WO1983003197A1 (en) * 1982-03-16 1983-09-29 Univ Rockefeller Method for controlling gastrointestinal dysmotility
US4519801A (en) * 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5021053A (en) * 1989-07-14 1991-06-04 Alza Corporation Oral osmotic device with hydrogel driving member
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5198229A (en) * 1991-06-05 1993-03-30 Alza Corporation Self-retaining gastrointestinal delivery device
US5460826A (en) * 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy

Also Published As

Publication number Publication date
DK0914097T3 (da) 2002-04-29
EP0914097A2 (en) 1999-05-12
DE69709646D1 (de) 2002-02-21
HK1019705A1 (en) 2000-02-25
WO1997033566A3 (en) 1997-11-06
EP0914097B1 (en) 2002-01-16
ATE211906T1 (de) 2002-02-15
US5866164A (en) 1999-02-02
WO1997033566A2 (en) 1997-09-18
ES2168610T3 (es) 2002-06-16
DE69709646T2 (de) 2002-08-14
AU2059297A (en) 1997-10-01

Similar Documents

Publication Publication Date Title
PT914097E (pt) Composicao e forma de dosagem compreendendo antagonista de opioide
EE9800173A (et) Gonadotropiini riliisinghormooni antagonistid
DE60014400D1 (de) Antiadhäsionsschicht aus hyaluronsäure
LU90987I2 (fr) Copaxone et ses dérivés pharmaceutiquement acceptables
FI965203A0 (fi) Morfiinia, polypyrrolidonia ja polyalkyleenioksidia sisältävä koostumus
BR9813228A (pt) Formulação de 2-metil-tieno-benzodiazepina
BR0103339A (pt) Sistema de comunicação cdma para designar flexivelmente códigos de difusão de acordo com tráfego
EE9700113A (et) Madala molekulmassiga bitsüklilised trombiini inhibiitorid
ATE214928T1 (de) Thrombininhibitoren
EE200200349A (et) Antiprogestiinsete omadustega ravimite manustamise vahendid
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
BR0007589A (pt) Inibidores da proliferação de células
TR200000374T2 (tr) Akut akciğer harabiyeti ve fibrozitinin alfavbeta6 antagonistleriyle tedavisi.
PL323490A1 (en) Tetralinic compounds exibiting acitity against multgiple-drug refractoriness
PT921787E (pt) Regime de administracao de inibidores de atpase de h',k'
DE10084671T1 (de) Pharmazeutische Zusammensetzungen
NZ333723A (en) A synergistic combination of an insulin resistance improving agent and an angiotensin II receptor antagonist or an angiotensin converting enzyme inhibitor
HRPK20030734B3 (en) A combination comprising combretastatin and anticancer agents
ITMI962385A0 (it) Diaril-ciclometilenpirazoli farmacologicamente attivi procedimento per prepararli e composizioni farmaceutiche che li contengono
DE69935873D1 (de) 2-Methyl-thieno-benzodiazepin Formulierung
ATE450254T1 (de) Schwimmende pharmazeutische zusammensetzung mit einer aktiven phase und einer inaktiven phase
NZ517872A (en) Multidrug efflux pumps
DK1212119T3 (da) Anvendelse af cyamemazin ved behandling af brat seponering af benzodiazepiner
BR9902081A (pt) Combinação de dofetilida e um bloqueador dos canais de cálcio
FI981833A0 (fi) Menetelmä aikaohjautuvan tavoitettavuuspalvelun toteuttamiseksi ja tilapäisen kutsunsiirron ominaisuuksien määrittelemiseksi